Sun Pharma Advanced Research stated on January 8, 2026, that it will be decreasing its headcount by 40%.
As part of its plans, Sun Pharma is planning to remove over 80% of its employees based in the US in a bid to optimise cost and boost growth. It is projected that, by FY27, Sun Pharma’s workforce count will be at 246, significantly less than 409 in FY24. The company is also planning to consolidate its lab operations from four locations to two, between Vadodara and Mumbai.
“Focussed cost optimisation has led to about $10 million in annual savings, strengthening operational efficiency and improving long-term financial sustainability,” Sun Pharma said in a presentation. The company is also switching to a hybrid work model from a fully captive one.
The company is looking to partly outsource its research work to clinical research organisations or contract development and manufacturing organisations, a company official added. Previously, it had done all its research in-house. Sun Pharma currently has an outstanding debt of $46 million. Hence, the company has taken many steps to reduce its operational costs in order to increase savings.
